Article Sidebar
Published:
Oct 29, 2022Keywords:
Article Details
Submission of a paper for publication implies the transfer of the copyright from the author(s) to the publisher upon acceptance. International Formulae Group is therefore the copyright holder after publication of an article in International Journal of Biological and Chemical Sciences, and published articles should not be used for commercial purpose without the written consent of the Editor-in-Chief. They are licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License.
Main Article Content
Lactate dehydrogenase (LDH) and evaluation of response to breast cancer chemotherapy
Abstract
Breast cancer is the leading cause of cancer death in women worldwide. The aim of this study was to determine the value of post-therapy serum LDH in assessing response at the completion of chemotherapy in breast cancer patients. This was a prospective cross-sectional study with data collection from May 2019 to November 2020, at the University Hospital of Bogodogo and at the SANDOF Polyclinic. We performed the LDH assay on serum from patients at the end of breast cancer chemotherapy who were at least 18 years old. Thirty (30) patients were included, with a mean age of 47.47 ± 2.10 years. Based on RECIST criteria, 46.67% had a successful response to chemotherapy, while 53.33% had a poor response. The mean post-therapy serum LDH was 256.15±25.99 U/L and 46.67% of patients had elevated serum LDH. Mean serum LDH was significantly higher in patients with a personal history of breast cancer (p=0.0198), increased CA 15-3 (p=0.0489) and poor response to chemotherapy (p=0.0291). Serum LDH was significantly higher in patients with a poor response to chemotherapy. Further studies are required to establish a more reliable correlation between serum LDH levels and response to breast cancer chemotherapy.
